flurbiprofen; 5104-49-4; Ansaid; Froben; Antadys; 2-(2-fluorobiphenyl-4-yl)propanoic acid; 2-(3-fluoro-4-phenylphenyl)propanoic acid; Flubiprofen; 3-Fluoro-4-phenylhydratropic acid; Cebutid; Flurofen; Flurbiprofene; Flurbiprofeno; Flurbiprofenum; Ocufen; Flurbiprofene [INN-French]; Flurbiprofenum [INN-Latin]; Flurbiprofeno [INN-Spanish]; C15H13FO2; FP 70; BTS 18322; BTS-18322; U-27182; 2-Fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid; (+-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; CCRIS 3708; 51543-38-5; U 27182; 2-(2-Fluorobiphenyl-4-yl)propionic Acid; UNII-5GRO578KLP; EINECS 225-827-6; 5GRO578KLP; MFCD00079303; Stayban; Zepolas; Adfeed; 2-(2-FLUORO-[1,1'-BIPHENYL]-4-YL)PROPANOIC ACID; BTS 18,322; NSC-757037; (+-)-2-(2-Fluoro-4-biphenylyl)propionic acid; CHEBI:5130; DTXSID0037231; CHEMBL563; (+/-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; U-27,182; 2-(2-Fluoro-4-biphenylyl)propionic acid; MLS000040873; Fluriproben; DTXCID8017231; Flugalin; 4-Biphenylacetic acid, 2-fluoro-alpha-methyl-; 2-Fluoro-alpha-methyl-4-biphenylacetic acid; NSC685701; NSC 757037; Flurbiprofen [USAN:USP:INN:BAN:JAN]; Ocuflur; SMR000042823; (1,1'-Biphenyl)-4-acetic acid, 2-fluoro-alpha-methyl-, (+-)-; Flurbiprofene (INN-French); Flurbiprofenum (INN-Latin); Flurbiprofeno (INN-Spanish); FLURBIPROFEN (MART.); FLURBIPROFEN [MART.]; 2-fluoro--methyl-(1,1'-biphenyl)-4-acetic acid; FLURBIPROFEN (USP-RS); FLURBIPROFEN [USP-RS]; 2-(2-fluoro-[1,1'-biphenyl-4-yl])propanoic acid; (+/-)-2-(2-FLUORO-4-BIPHENYLYL)PROPIONIC ACID; Anmetarin; Yakuban; dl-Flurbiprofen; FLURBIPROFEN (EP MONOGRAPH); FLURBIPROFEN [EP MONOGRAPH]; [1,1'-Biphenyl]-4-acetic acid, 2-fluoro-a-methyl-, (A+/-)-; FLURBIPROFEN (USP MONOGRAPH); FLURBIPROFEN [USP MONOGRAPH]; (1,1'-Biphenyl)-4-acetic acid, 2-fluoro-alpha-methyl-, (+/-)-; Flurbiprofen (Ansaid); Flurbiprofen (USAN:USP:INN:BAN:JAN); Ansaid (TN); SR-01000003043; FLP; (R)-Flurbiprofen;MPC7869; 2-(2-fluoro-(1,1'-biphenyl-4-yl))propanoic acid; MPC7869; U 27,182; Flurbiprofen; (2RS)-2-(2-Fluorobiphenyl-4-yl)propanoic acid; Flurbiprofen O; (1,1'-Biphenyl)-4-acetic acid, 2-fluoro-alpha-methyl-; MKS-11; rac-Flurbiprofen; Flurbiprofen,(S); NCGC00016654-01; (+-)Flurbiprofen; CAS-5104-49-4; EINECS 257-262-6; L-790,330; Ocufen (Salt/Mix); [1,1'-Biphenyl]-4-acetic acid, 2-fluoro-?-methyl-; (1)-2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic acid; Flurbiprofen (NSAID); Spectrum_001096; Opera_ID_777; Prestwick0_000917; Prestwick1_000917; Prestwick2_000917; Prestwick3_000917; Spectrum2_001025; Spectrum3_000435; Spectrum4_000558; Spectrum5_000720; FLURBIPROFEN [MI]; 2-(3-fluoro-4-phenyl-phenyl)propanoic acid; F0371; (.+/-.)-Flurbiprofen; 2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic acid; FLURBIPROFEN [INN]; FLURBIPROFEN [JAN]; Antiphlamine Pain Relieving; FLURBIPROFEN [USAN]; SCHEMBL2248; FLURBIPROFEN [VANDF]; 4-Biphenylacetic acid, 2-fluoro-.alpha.-methyl-; BSPBio_000794; BSPBio_002050; KBioGR_001255; KBioSS_001576; MLS000028441; MLS000758198; MLS001201729; MLS001401361; MLS006011431; MLS006011931; DivK1c_000804; FLURBIPROFEN [WHO-DD]; SPECTRUM1500308; SPBio_001209; SPBio_002983; BPBio1_000874; GTPL4194; SCHEMBL10029029; Flurbiprofen (JP17/USP/INN); HMS502I06; KBio1_000804; KBio2_001576; KBio2_004144; KBio2_006712; KBio3_001270; SYTBZMRGLBWNTM-UHFFFAOYSA-; [1,1'-Biphenyl]-4-acetic acid, 2-fluoro-.alpha.-methyl-; M01AE09; M02AA19; R02AX01; S01BC04; NINDS_000804; FLURBIPROFEN [ORANGE BOOK]; HMS1570H16; HMS1920O20; HMS2051A05; HMS2090I06; HMS2091F21; HMS2097H16; HMS2232I08; HMS3259I12; HMS3268E10; HMS3370N14; HMS3371I05; HMS3393A05; HMS3414N17; HMS3649K11; HMS3655G19; HMS3678N15; HMS3714H16; Pharmakon1600-01500308; 2-FLUORO-[1,1'-BIPHENYL]-4-(ALPHA-METHYL)ACETIC ACID; BCP09086; BCP13426; Tox21_110547; Tox21_302353; BBL010980; BDBM50074922; CCG-40243; Flurbiprofen - CAS 5104-49-4; HB3049; NSC755404; NSC757037; STK802101; Flurbiprofen, cyclooxygenase inhibitor; AKOS004119934; AKOS016340701; AC-8106; CCG-100759; DB00712; KS-5035; MCULE-4306860727; NC00009; NC00563; NSC-685701; NSC-755404; 2(2-Fluoro-4-biphenylyl)propionic acid; IDI1_000804; NCGC00018157-03; NCGC00018157-04; NCGC00018157-05; NCGC00018157-08; NCGC00018157-11; NCGC00018157-13; NCGC00025287-03; NCGC00025287-04; NCGC00255457-01; HY-10582; NCI60_030812; 2 -(2-fluoro-4-biphenylyl)propionic acid; 2-(2-fluoro-4-biphenylyl)-propionic acid; 2-(2-fluoro-biphenyl-4-yl)propionic acid; SBI-0051387.P003; DB-051888; 2-(2-fluoro-biphenyl-4-yl)-propionic acid; AB00051999; NS00003058; alpha-methyl-2-fluoro-4-biphenylylacetic acid; (RS)-2-(2-fluorobiphenyl-4-yl)propionic acid; 2-Fluoro-.alpha.-methyl-4-biphenylacetic acid; BIM-0051387.0001; C07013; D00330; AB00051999-17; AB00051999_18; EN300-7479231; (2RS)-2-(2-Fluorobiphenyl-4-yl)propanoic acid; 2-(2-Fluoro-1,1'-biphenyl-4-yl)propanoic acid; 2-(2-Fluoro[1,1'-biphenyl]-4-yl)propanoic acid; AO-295/42284050; Q419890; (.+/-.)-2-(2-Fluoro-4-biphenylyl)propionic acid; (r/s)-2-fluoro-alpha-methyl-4-biphenylacetic acid; Flurbiprofen, Antibiotic for Culture Media Use Only; Q-201129; SR-01000003043-2; SR-01000003043-5; SR-01000003043-6; (S)-(+)-2-Fluoro-alpha-methyl-4-biphenylaceticacid; 2-(2-fluoro-[1,1''-biphenyl-4-yl])propanoic acid; 2-(2-Fluoro[1,1'-biphenyl]-4-yl)propanoic acid #; BRD-A86044036-001-05-9; SR-01000003043-14; (.+/-.)-2-Fluoro-.alpha.-methyl-4-biphenylacetic acid; 2-Fluoro-.alpha.-methyl(1,1'-biphenyl)-4-acetic acid; 2-fluoro-alpha-methyl-(1,1''-biphenyl)-4-acetic acid; 2-Fluoro-alpha-methyl-[1,1'-biphenyl]-4-a cetic acid; Z2216885233; (+/-)-2-FLUORO-.ALPHA.-METHYL-4-BIPHENYLACETIC ACID; Flurbiprofen, European Pharmacopoeia (EP) Reference Standard; Flurbiprofen, United States Pharmacopeia (USP) Reference Standard; [1,1'-Biphenyl]-4-acetic acid, 2-fluoro-.alpha.-methyl-, (.+/-.)-; (1,1'-BIPHENYL)-4-ACETIC ACID, 2-FLUORO-.ALPHA.-METHYL-, (+/-)-; Flurbiprofen, 2-(2-Fluorobiphenyl-4-yl)propionic acid, 3-Fluoro-4-phenylhydratropic acid; Flurbiprofen, Pharmaceutical Secondary Standard; Certified Reference Material; InChI=1/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)